Deconvolution of transcriptomes and miRNomes by independent component analysis provides insights into biological processes and clinical outcomes of melanoma patients.
Cancer
Deconvolution
Independent component analysis
Survival analysis
Transcriptomics
Journal
BMC medical genomics
ISSN: 1755-8794
Titre abrégé: BMC Med Genomics
Pays: England
ID NLM: 101319628
Informations de publication
Date de publication:
18 09 2019
18 09 2019
Historique:
received:
20
03
2019
accepted:
05
09
2019
entrez:
20
9
2019
pubmed:
20
9
2019
medline:
3
4
2020
Statut:
epublish
Résumé
The amount of publicly available cancer-related "omics" data is constantly growing and can potentially be used to gain insights into the tumour biology of new cancer patients, their diagnosis and suitable treatment options. However, the integration of different datasets is not straightforward and requires specialized approaches to deal with heterogeneity at technical and biological levels. Here we present a method that can overcome technical biases, predict clinically relevant outcomes and identify tumour-related biological processes in patients using previously collected large discovery datasets. The approach is based on independent component analysis (ICA) - an unsupervised method of signal deconvolution. We developed parallel consensus ICA that robustly decomposes transcriptomics datasets into expression profiles with minimal mutual dependency. By applying the method to a small cohort of primary melanoma and control samples combined with a large discovery melanoma dataset, we demonstrate that our method distinguishes cell-type specific signals from technical biases and allows to predict clinically relevant patient characteristics. We showed the potential of the method to predict cancer subtypes and estimate the activity of key tumour-related processes such as immune response, angiogenesis and cell proliferation. ICA-based risk score was proposed and its connection to patient survival was validated with an independent cohort of patients. Additionally, through integration of components identified for mRNA and miRNA data, the proposed method helped deducing biological functions of miRNAs, which would otherwise not be possible. We present a method that can be used to map new transcriptomic data from cancer patient samples onto large discovery datasets. The method corrects technical biases, helps characterizing activity of biological processes or cell types in the new samples and provides the prognosis of patient survival.
Sections du résumé
BACKGROUND
The amount of publicly available cancer-related "omics" data is constantly growing and can potentially be used to gain insights into the tumour biology of new cancer patients, their diagnosis and suitable treatment options. However, the integration of different datasets is not straightforward and requires specialized approaches to deal with heterogeneity at technical and biological levels.
METHODS
Here we present a method that can overcome technical biases, predict clinically relevant outcomes and identify tumour-related biological processes in patients using previously collected large discovery datasets. The approach is based on independent component analysis (ICA) - an unsupervised method of signal deconvolution. We developed parallel consensus ICA that robustly decomposes transcriptomics datasets into expression profiles with minimal mutual dependency.
RESULTS
By applying the method to a small cohort of primary melanoma and control samples combined with a large discovery melanoma dataset, we demonstrate that our method distinguishes cell-type specific signals from technical biases and allows to predict clinically relevant patient characteristics. We showed the potential of the method to predict cancer subtypes and estimate the activity of key tumour-related processes such as immune response, angiogenesis and cell proliferation. ICA-based risk score was proposed and its connection to patient survival was validated with an independent cohort of patients. Additionally, through integration of components identified for mRNA and miRNA data, the proposed method helped deducing biological functions of miRNAs, which would otherwise not be possible.
CONCLUSIONS
We present a method that can be used to map new transcriptomic data from cancer patient samples onto large discovery datasets. The method corrects technical biases, helps characterizing activity of biological processes or cell types in the new samples and provides the prognosis of patient survival.
Identifiants
pubmed: 31533822
doi: 10.1186/s12920-019-0578-4
pii: 10.1186/s12920-019-0578-4
pmc: PMC6751789
doi:
Substances chimiques
MicroRNAs
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
132Références
Nature. 2013 Jul 11;499(7457):214-218
pubmed: 23770567
Bioinformatics. 2019 Nov 1;35(21):4307-4313
pubmed: 30938767
Biostatistics. 2007 Jan;8(1):118-27
pubmed: 16632515
Clin Cancer Res. 2010 Mar 1;16(5):1577-86
pubmed: 20179230
J Biol Chem. 2017 Nov 10;292(45):18530-18541
pubmed: 28912267
BMC Genomics. 2017 Jun 6;18(1):443
pubmed: 28587590
Genome Med. 2013 Mar 28;5(3):29
pubmed: 23537167
Nucleic Acids Res. 2018 Jan 4;46(D1):D296-D302
pubmed: 29126174
BMC Genomics. 2015 Dec 01;16:1022
pubmed: 26626453
Cell. 2015 Jun 18;161(7):1681-96
pubmed: 26091043
Biochem Biophys Res Commun. 2013 Jan 18;430(3):1182-7
pubmed: 23261450
Oncotarget. 2016 Dec 6;7(49):80957-80966
pubmed: 27829231
Pigment Cell Melanoma Res. 2016 May;29(3):266-83
pubmed: 26833684
Nucleic Acids Res. 2016 Jul 8;44(W1):W90-7
pubmed: 27141961
Science. 2000 Dec 22;290(5500):2323-6
pubmed: 11125150
Oncogene. 2015 Jan 2;34(1):94-103
pubmed: 24317514
Proc Natl Acad Sci U S A. 2015 Jan 13;112(2):476-81
pubmed: 25548153
Nat Commun. 2019 Apr 16;10(1):1787
pubmed: 30992437
Commun Biol. 2023 Feb 25;6(1):222
pubmed: 36841852
Nucleic Acids Res. 2013 Mar 1;41(5):2817-31
pubmed: 23335783
Science. 2000 Dec 22;290(5500):2319-23
pubmed: 11125149
Cancer Metastasis Rev. 2016 Jun;35(2):289-322
pubmed: 26970968
Nat Methods. 2015 May;12(5):453-7
pubmed: 25822800
PLoS Comput Biol. 2007 Aug;3(8):e161
pubmed: 17708679
BMC Bioinformatics. 2010 Jul 02;11:367
pubmed: 20598126
Science. 2014 Jun 20;344(6190):1396-401
pubmed: 24925914
Circ Res. 2014 Sep 26;115(8):696-708
pubmed: 25085941
Genom Data. 2016 Feb 23;8:4-15
pubmed: 27081632
PLoS One. 2014 Apr 14;9(4):e95224
pubmed: 24733377
Nature. 2008 Mar 13;452(7184):225-9
pubmed: 18311128
Cell Rep. 2014 Nov 20;9(4):1235-45
pubmed: 25456126
Genome Biol. 2010;11(10):R106
pubmed: 20979621
Genome Biol. 2003;4(11):R76
pubmed: 14611662
Genomics Proteomics Bioinformatics. 2008 Jun;6(2):74-82
pubmed: 18973863
Cancer Lett. 2018 Aug 28;430:172-178
pubmed: 29800683
Proc Natl Acad Sci U S A. 2009 Dec 1;106(48):20429-34
pubmed: 19915147
Oncotarget. 2011 Dec;2(12):1265-78
pubmed: 22246208
Mol Cancer. 2012 Jul 02;11:44
pubmed: 22747855
Pharmacogenomics J. 2004;4(3):193-207
pubmed: 15037859
Bioinformatics. 2008 May 1;24(9):1154-60
pubmed: 18325927
Clin Cancer Res. 2016 Aug 15;22(16):4095-104
pubmed: 27151745
Science. 2016 Apr 8;352(6282):189-96
pubmed: 27124452
Proc Natl Acad Sci U S A. 2014 Jul 22;111(29):10773-8
pubmed: 25002493
Nucleic Acids Res. 2017 Jan 4;45(D1):D362-D368
pubmed: 27924014
Genome Biol. 2016 Apr 29;17:80
pubmed: 27139883
Biol Direct. 2013 Apr 24;8:10
pubmed: 23618224
Nat Commun. 2013;4:2612
pubmed: 24113773
Mol Biol Evol. 2016 Sep;33(9):2232-47
pubmed: 27189568